Brief: Nuvectis Pharma Reports Third Quarter Results
08/11/2022 15:41
Nov 8 (Reuters) - Nuvectis Pharma Inc NVCT.O :
* NUVECTIS PHARMA, INC. REPORTS THIRD QUARTER 2022 FINANCIAL
RESULTS AND BUSINESS HIGHLIGHTS
* NUVECTIS PHARMA - DOSE ESCALATION PORTION OF PHASE 1
CLINICAL
TRIAL OF NXP800 IS ONGOING, PHASE 1B DOSE EXPANSION PORTION
EXPECTED TO BEGIN IN Q1 2023
* NUVECTIS PHARMA - INVESTIGATIONAL NEW DRUG
APPLICATION-ENABLING
STUDIES FOR NXP900 ARE ONGOING, SUBMISSION OF IND OR EQUIVALENT
EXPECTED IN Q1 2023
* NUVECTIS PHARMA INC - CONTINUE TO OPERATE EFFICIENTLY WITH
AN
EXPECTED CASH RUNWAY INTO SECOND HALF OF 2024
* NUVECTIS PHARMA INC - QTRLY LOSS PER SHARE $0.42
Source text for Eikon: ID:nGNX678fBX
Further company coverage: NVCT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Nuvectis Pharma
See all newsNuvectis Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Ciprocopan (NXP100) Receives Marketing Approval In China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin